Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Data from a safety study evaluating AstraZeneca's Pulmicort Respules has shown that long term use of the product was well-tolerated in children with severe, oral corticosteroid-dependent asthma inadequately controlled by previous therapy.
Subscribe to our email newsletter
The open label safety study evaluated 397 pediatric asthma patients between the ages of six months and eight years over the course of one and a half years.
Pulmicort Respules is delivered by a jet nebulizer. This type of nebulizer uses air pressure to turn the medicine into a mist that is then inhaled through a facemask or a mouthpiece. A compressor connected to the nebulizer controls the airflow to the facemask or the mouthpiece, a method that may make delivery more consistent.
Pulmicort Respules is the only nebulized inhaled corticosteroid approved in the US for children with asthma as young as 12 months.
“Identifying an asthma therapy that is well-tolerated over a long-term period of use can be a challenging step in continuing the health of children with asthma, particularly those with severe asthma who are not controlled on other treatments,” said Dr Bradley Chipps, medical director at the Capital Allergy and Respiratory Disease Center in California. “This study showed that nebulized therapy with Pulmicort Respules may be an important long-term treatment to help manage children with severe asthma.”